Phase 4 N=20 Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
Prediabetes · Obesity
Primary: Monocyte NfkB Levels as Detected by Western Blotting — 62.79; 72.03; 67.68; 84.19 NfkB p65 arbitrary units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=72 A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Postprandial Pulse Wave Velocity (PWV) in Type 2 Diabetes Mellitus (T2DM) Participants at 30 Minutes (Mins) Pre-Breakfast — 10.99; 10.73; 11.56; 11.31 meters per second…
N/A N=7 Continuous Glucose Monitoring to Measure Effect of Glycemic Index
Type 1 Diabetes Mellitus
Primary: Mean Area Under the Curve for Rise in Breakfast Post-prandial. — 61; 583 min x (mmol/l)
Phase 2 N=9 Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects
Postbariatric Hypoglycemia
Primary: Glucose Nadir After Mizagliflozin Dosing — 6.2; 4.0; 17.5; 31.5 mg/dL
N/A N=7 Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia
Postprandial Hypoglycemia
Primary: Mean Plasma Glucose Area Under the Curve (AUC 0-3h) — 22,192.5; 25,207.1; 21,715.9 mg*min/dl
Phase 4 N=1,116 Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
Diabetes Mellitus, Type 2 · Acute Myocardial Infarction
Primary: Number of Participants Who Experienced a Primary Combined Outcome — 174; 181 participants — p=0.866
Phase 3 N=36 Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes
Diabetes Mellitus · Postprandial Lipemia
Primary: Measurement of the Area Under the Curve of Plasma Triglycerides (TG) Levels During Postprandial Period (Time 0,2,4,6,8 Hours) — 30.0; 27.1 mmol*h/L
Phase 3 N=60 Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment — -18.07; -103.56; -122.94 mg*h/dL…
Phase 4 N=14 Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Mean ApoB Concentration Before and After Evolocumab — 75.9; 35.3 mg/dL — p=<0.001
Phase 2 N=30 Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L
N/A N=99 Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia
Type 1 Diabetes
Primary: The Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Lunch. — 146.69; 143.68; 149.02 mg/dl — p=.971
Phase 4 N=160 Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4) — -1.775; -2.434 mmol/L
Phase 1 N=22 Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans
Insulin Resistance, Diabetes
Primary: Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours — 301.09; 258.66; 248.63; 274.13 mmol x min/L — p=0.1146
Phase 2 N=60 BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in Subjects With Pre-Diabetes
Pre-Diabetes
Primary: Change in Serum Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo — -5.2; -9.4; -8.8 umol/L — p=0.57
N/A N=40 Glycemic Responses to Majia Pomelos in Type 2 Diabetic Patients
Diabetes
Primary: Glycemic Index — 76.79; 86.92 percentage of AUC from GI100 — p=0.005
N/A N=34 Effects of an Apple Extract on Glycaemia: The GLU-Pomme Study
Prevention of Hyperglycaemia
Primary: Postprandial Glycaemia — 11.3; 15.2; 17.8; 27.1 mmol/L*min
N/A N=56 Effect of Dietary Glycemic Index on Beta-cell Function
Impaired Glucose Tolerance · Oxidative Stress · Prediabetes
Primary: Disposition Index — 708; 793; 791 unitless
N/A N=30 Glycemic Optimization On Discharge From the Emergency Room
Diabetes Mellitus
Primary: Change in Diabetes Distress — 0; 0.5 units on a scale
Phase 2 N=16 Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia
Post-bariatric Hypoglycemia
Primary: Number of Participants With Meal-provoked Hypoglycemia, Defined as Sensor Glucose <65 mg/dL — 1; 5 participants — p=0.103
N/A N=14 The Effect of Dietary Fiber-enriched Cereals on Glycemic Control and Secretion of Gut Hormones
Diabetes Mellitus
Primary: Area Under the Curve (AUC) of Plasma Total GLP-1 Levels After Intake of the Study Meal — 10.5; 10.5 pM x hr/L
N/A N=35 Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability
Type 1 Diabetes Mellitus
Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL
Phase 4 N=36 Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM
Disorder of Glucose Regulation
Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035
N/A N=1,939 Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care
Type 2 Diabetes Mellitus · Prediabetic State
Primary: Ability of Different Screening Tests Which Can be Performed Opportunistically (During Outpatient Visits -- at Any Time of Day, Regardless of Meal Status) to Predict…
Phase 4 N=22 Incretins in Impaired Fasting Glucose
Pre-diabetes
Primary: Lowering of Fasting Glucose — 5.78; 5.83 mmol/l — p=>0.05
N/A N=19 Post-Prandial Liver Glucose Metabolism in PCOS
Polycystic Ovarian Syndrome · Obesity · Hepatic Steatosis
Primary: Hepatic Fat Fraction — 8.35 Percent
Phase 2 N=74 Glycemic Control and Variability for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
N/A N=235 Point-of-Care Glucose Testing and Insulin Supplementation
Diabetes
Primary: Mean Fasting Blood Glucose — 162; 157 mg/dL
Phase 2 N=74 Intensive Glycemic Control for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
Phase 3 N=12 New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy
Type 1 Diabetes
Primary: The Area Under the Curve (AUC) of Plasma Glucose (PG) Concentrations During the 5-hour Postprandial Period (AUC-PG0-5 h). — 724.6; 668.8 mg*h/dl
Phase 4 N=23 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
Non-Insulin-Dependent Diabetes Mellitus
Primary: Duration of Hyperglycaemia (>126 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment — 17.31; 17.53; 15.30; 10.83 Hours — p=0.064